Monitors safety of Tafinlar and Mekinist in advanced solid tumors with BRAF V600E
Observes people with advanced solid tumors carrying a BRAF V600E mutation taking Tafinlar and Mekinist.
Plain-language title generated from the registry record
Registry title: Special Drug Use-results Surveillance of Tafinlar/Mekinist
Key facts
- Where
- Akita, Amagasaki, Bunkyo Ku, Chiba, Chuo Ku, Daisen, Fukuoka, Fukuyama, Funabashi, Habikino, Hiroshima, Iida, Izumisano, Kagoshima, Kashiwa, Kawagoe, Kobe, Kochi, Kurume, Kyoto, Matsumoto, Minato Ku, Mito, Morioka, Nagakute, Nagoya, Natori-shi, Ohtsu, Okayama, Osaka, Sagamihara, Saitama, Sapporo, Sendai, Setagaya-ku, Shibuya City, Shimotsuke, Shinjuku Ku, Shizuoka, Sunto Gun, Takatsuki, Toyohashi, Toyota, Wakayama, Yamagata, Yokohama, Yoshida-gun, and Yufu, JapanSee the 48 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 99 years old?
Source: NCT06262919, who can take part
Where in Japan
- AkitaAkita, JapanNo longer taking part
- AmagasakiAmagasaki, JapanNo longer taking part
- Bunkyo KuBunkyo Ku, JapanTaking people
- ChibaChiba, JapanNo longer taking part
- Chuo KuChuo Ku, JapanTaking people
- DaisenDaisen, JapanNo longer taking part
- FukuokaFukuoka, JapanTaking people
- FukuyamaFukuyama, JapanTaking people
- FunabashiFunabashi, JapanNo longer taking part
- HabikinoHabikino, JapanNo longer taking part
- HiroshimaHiroshima, JapanTaking people
- IidaIida, JapanNo longer taking part
- IzumisanoIzumisano, JapanNo longer taking part
- KagoshimaKagoshima, JapanTaking people
- KashiwaKashiwa, JapanTaking people
- KawagoeKawagoe, JapanTaking people
- KobeKobe, JapanNo longer taking part
- KochiKochi, JapanTaking people
- KurumeKurume, JapanTaking people
- KyotoKyoto, JapanTaking people
- MatsumotoMatsumoto, JapanTaking people
- Minato KuMinato Ku, JapanTaking people
- MitoMito, JapanTaking people
- MoriokaMorioka, JapanNo longer taking part
- NagakuteNagakute, JapanNo longer taking part
- NagoyaNagoya, JapanTaking people
- Natori-shiNatori-shi, JapanNo longer taking part
- OhtsuOhtsu, JapanTaking people
- OkayamaOkayama, JapanTaking people
- OsakaOsaka, JapanTaking people
- SagamiharaSagamihara, JapanTaking people
- SaitamaSaitama, JapanTaking people
- SapporoSapporo, JapanTaking people
- SendaiSendai, JapanTaking people
- Setagaya-kuSetagaya-ku, JapanTaking people
- Shibuya CityShibuya City, JapanNo longer taking part
- ShimotsukeShimotsuke, JapanNo longer taking part
- Shinjuku KuShinjuku Ku, JapanNo longer taking part
- ShizuokaShizuoka, JapanTaking people
- Sunto GunSunto Gun, JapanTaking people
- TakatsukiTakatsuki, JapanTaking people
- ToyohashiToyohashi, JapanNo longer taking part
- ToyotaToyota, JapanNo longer taking part
- WakayamaWakayama, JapanNo longer taking part
- YamagataYamagata, JapanNo longer taking part
- YokohamaYokohama, JapanTaking people
- Yoshida-gunYoshida-gun, JapanTaking people
- YufuYufu, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06262919
- Record updated
- 17 June 2026
- Original description
This is a prospective, multicenter, single-arm, non-interventional and observational J-PMS conducted by the central registration system and operated in Electronic data capture.Read full original descriptionShow less
Observational Study to Assess Safety and Effectiveness of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
This is a prospective, multicenter, single-arm, non-interventional and observational J-PMS conducted by the central registration system and operated in Electronic data capture.
Inclusion: Patients who have given written consent to cooperate in this surveillance; For patients aged < 18 years at the start of treatment with the product, their legally authorized representative must have given written informed consent for cooperation in this surveillance prior to patient enrollment; Patients who start treatment with the product for BRAF-mutation-positive advanced/recurrent solid tumors (excluding colorectal cancer) after the approval of additional indications.
Exclusion: Patients who have received or are receiving a product containing the same ingredient as the product in any other study or research than this surveillance; Patients with BRAF-mutation-positive malignant melanoma; Patients with BRAF-mutation-positive non-small cell lung cancer; Patients with BRAF-mutation-positive hairy cell leukemia.